Literature DB >> 19756374

Dysphonia induced by vascular endothelium growth factor/vascular endothelium growth factor receptor inhibitors.

Dana M Hartl1, Charles Ferté, Yohann Loriot, Carlos Gomez Roca, Rastislav Bahleda, Cristian Moldovan, Olivier Mir, Jean-Charles Soria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19756374     DOI： 10.1007/s10637-009-9314-9

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  7 in total

1.  Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.

Authors:  Frank A Scappaticci; Louis Fehrenbacher; Thomas Cartwright; John D Hainsworth; William Heim; Jordan Berlin; Fairooz Kabbinavar; William Novotny; Somnath Sarkar; Herbert Hurwitz
Journal:  J Surg Oncol       Date:  2005-09-01       Impact factor: 3.454

2.  [The Voice Handicap Index: impact of the translation in French on the validation].

Authors:  V Woisard; S Bodin; M Puech
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  2004

3.  Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Authors:  Charles Ferté; Christophe Massard; Christian Moldovan; Eric Desruennes; Yohann Loriot; Jean-Charles Soria
Journal:  Invest New Drugs       Date:  2009-02-17       Impact factor: 3.850

4.  Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

Authors:  Vincent Launay-Vacher; Gilbert Deray
Journal:  Anticancer Drugs       Date:  2009-01       Impact factor: 2.248

5.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Authors:  Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz
Journal:  J Natl Cancer Inst       Date:  2007-08-08       Impact factor: 13.506

Review 6.  Management of hypertension in angiogenesis inhibitor-treated patients.

Authors:  H Izzedine; S Ederhy; F Goldwasser; J C Soria; G Milano; A Cohen; D Khayat; J P Spano
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

7.  Rhinitis and epistaxis in patients treated by anti-angiogenic therapy.

Authors:  V Prulière-Escabasse; E Escudier; R Balheda; J C Soria; A Coste; C Massard
Journal:  Invest New Drugs       Date:  2008-08-27       Impact factor: 3.850
  7 in total
  4 in total

1.  [Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].

Authors:  V Lieb; M Rink; D Sikic; B Keck
Journal:  Urologe A       Date:  2016-06       Impact factor: 0.639

Review 2.  Dysphonia induced by anti-angiogenic compounds.

Authors:  Erika Saavedra; Antoine Hollebecque; Jean-Charles Soria; Dana M Hartl
Journal:  Invest New Drugs       Date:  2013-12-18       Impact factor: 3.850

Review 3.  Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma.

Authors:  Bo Hyun Kim; Su Jong Yu; Wonseok Kang; Sung Bum Cho; Soo Young Park; Seung Up Kim; Do Young Kim
Journal:  J Gastroenterol Hepatol       Date:  2021-11-17       Impact factor: 4.369

4.  Dysphonia after Bevacizumab Rechallenge: A Case Report.

Authors:  Corey A Carter; Scott Z Caroen; Arnold L Oronsky; Bryan T Oronsky
Journal:  Case Rep Oncol       Date:  2015-10-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.